Clinical Validation of the Intermediate-risk Non–muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group Collaboration

This publication has 10 references indexed in Scilit:

• Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group
  Journal of Clinical Oncology, 2023
• International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance
  Journal of Urology, 2023
• Intermediate-risk Non–muscle-invasive Bladder Cancer: Time To Tidy Up the Mess?
  European Urology Oncology, 2022
• Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group
  European Urology Oncology, 2022
• European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)
  European Urology, 2022
• Stratification of Intermediate-risk Non–muscle-invasive Bladder Cancer Patients: Implications for Adjuvant Therapies
  European Urology Focus, 2021
• European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel
  European Urology, 2021
• Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline
  Journal of Urology, 2016
• Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation
  World Journal of Urology, 2015
• Defining and Treating the Spectrum of Intermediate Risk Nonmuscle Invasive Bladder Cancer
  Journal of Urology, 2014